Illumina, Inc. (VIE:ILMN)
Austria · Delayed Price · Currency is EUR | Market Cap | 24.76B +92.5% |
| Revenue (ttm) | 3.81B +1.3% |
| Net Income | 740.40M |
| EPS | 4.79 |
| Shares Out | n/a |
| PE Ratio | 33.44 |
| Forward PE | 34.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 164.20 |
| Previous Close | 163.96 |
| Day's Range | 164.20 - 164.20 |
| 52-Week Range | 77.71 - 170.58 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
News
Illumina adds three new member companies to Billion Cell Atlas alliance
Illumina (ILMN) announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. “As leaders in AI-driven drug discovery, design, ...
Illumina expands Billion Cell Atlas program with new AI drug developers
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell At...
Illumina price target raised to $192 from $140 at TD Cowen
TD Cowen raised the firm’s price target on Illumina (ILMN) to $192 from $140 and keeps a Hold rating on the shares. The firm adjusted targets in the tools space…
Illumina price target raised to $190 from $140 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Illumina (ILMN) to $190 from $140 and keeps a Hold rating on the shares. The firm updated its model ahead…
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. O...
Illumina appoints Sullivan as CCO, Coletti as CLO
Illumina (ILMN) announced the appointment of Mike Sullivan as Chief Commercial Officer, CCO, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, CLO, effective August 3, 2026. Most…
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the ap...
Illumina price target raised to $200 from $155 at Evercore ISI
Evercore ISI raised the firm’s price target on Illumina (ILMN) to $200 from $155 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Illumina price target raised to $200 from $170 at Piper Sandler
Piper Sandler raised the firm’s price target on Illumina (ILMN) to $200 from $170 and keeps an Overweight rating on the shares. The firm believes 10x Genomics and Illumina are…
Illumina price target raised to $200 from $180 at Guggenheim
Guggenheim raised the firm’s price target on Illumina (ILMN) to $200 from $180 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Illumina resumed with a Market Perform at Bernstein
Bernstein resumed coverage of Illumina (ILMN) with a Market Perform rating and $185 price target following a return from maternity leave. “Many things” are going right for the life science…
Illumina price target raised to $145 from $122 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Illumina (ILMN) to $145 from $122 and keeps an Underweight rating on the shares. The firm adjusted targets in the…
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc....
JPMorgan upgrades Illumina to Overweight after favorable customer survey
JPMorgan upgraded Illumina (ILMN) to Overweight from Neutral with a price target of $185, up from $125. JPMorgan cites Illumina’s customer “stickiness” and its favorable recent customer survey for the...
Illumina upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Casey Woodring upgraded Illumina (ILMN) to Overweight from Neutral with an $185 price target
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can gener...
Integrated DNA Technologies enters collaboration with Illumina
Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library...
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
Illumina price target raised to $180 from $170 at Guggenheim
Guggenheim raised the firm’s price target on Illumina (ILMN) to $180 from $170 and keeps a Buy rating on the shares after having hosted the CFO and IR team for…
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN)...
Illumina announces new complete solution for MRD research
Illumina (ILMN) announced a new complete solution for molecular residual disease research based on whole-genome sequencing. As a distributed kit, it will enable more labs to adopt MRD detection for…
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's hi...